XML 50 R37.htm IDEA: XBRL DOCUMENT
v3.23.1

LOSS PER SHARE | 12 Months Ended
--- | ---
Dec. 31, 2022
LOSS PER SHARE |
LOSS PER SHARE | 29. LOSS PER SHARE A reconciliation of net loss attributable to the Company in the consolidated statements of comprehensive loss to the numerator for the computation of basic and diluted loss per share for the years ended December 31, 2020, 2021 and 2022 is as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the Years Ended December 31,
​ | ​ | 2020 | ​ | 2021 | ​ | 2022 | ​ | 2022
​ |  | RMB |  | RMB |  | RMB |  | US$
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net loss attributable to Concord Medical Services Holdings Limited |  | (309,989) |  | (271,427) |  | (489,661) | ​ | (70,993)
Accretion of contingently redeemable noncontrolling interests |  | (359,920) |  | (549,194) |  | — | ​ | —
Numerator for EPS computation |  | (669,906) |  | (820,621) |  | (489,661) | ​ | (70,993)
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the Years Ended December 31
​ | ​ | 2020 | ​ | 2021 | ​ | 2022 | ​ | 2022
​ |  | Class A |  | Class B |  | Class A |  | Class B |  | Class A |  | Class A |  | Class B |  | Class B
​ | ​ | RMB | ​ | RMB | ​ | RMB | ​ | RMB | ​ | RMB | ​ | USD | ​ | RMB | ​ | USD
Numerator |  |  | ​ | ​ |  | ​ | ​ |  |  |  |  |  |  |  |  |
Net loss attributable to ordinary shareholders used in calculating loss per ordinary share – basic and diluted |  | (435,855) | ​ | (234,054) | ​ | (533,909) | ​ | (83,784) | ​ | (318,582) | ​ | (46,189) | ​ | (171,079) | ​ | (24,804)
Denominator: |  | ​ | ​ | ​ |  | ​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted average number of ordinary shares outstanding used in calculating loss per share – basic and diluted |  | 85,265,910 | ​ | 45,787,948 |  | 85,265,910 |  | 85,265,910 | ​ | 85,265,910 | ​ | 85,265,910 | ​ | 45,787,948 | ​ | 45,787,948
Loss per share – basic and diluted |  | (5.11) | ​ | (5.11) | ​ | (6.26) | ​ | (0.98) | ​ | (3.74) | ​ | (0.54) | ​ | (3.74) | ​ | (0.54)
​ The effects of share options and restricted shares have been excluded from the computation of diluted loss per share for the years ended December 31, 2020, 2021 and 2022 as their effects would be anti-dilutive.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI https://asc.fasb.org/topic&trid=2144383 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration